Page last updated: 2024-11-07

rp 48740

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(3-pyridinyl)-1H,3H-pyrrolo(1,2-c)thiazole-7-carboxamide: platelet activating factor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121869
CHEMBL ID67588
SCHEMBL ID9376223
MeSH IDM0149067

Synonyms (22)

Synonym
93363-11-2
48740-rp
rp-48740
rp 55779
rp 55778
1h,3h-pyrrolo[1,2-c]thiazole-7-carboxamide, 3-(3-pyridinyl)-
CHEMBL67588
rp-55778
3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
rp 48740
1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide, 3-(3-pyridinyl)-
rp-55779
48740 rp
48740rp
3-(3-pyridinyl)-1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide
SCHEMBL9376223
AKOS028110797
rp48740
CS-0018141
HY-100153
DTXSID50869725
3-(pyridin-3-yl)-1h,3h-pyrrolo[1,2-c][1,3]thiazole-7-carboxamide

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with RP 48740 either attenuated or abolished the ability of inhaled LPS to induce these structural alterations."( The role of platelet-activating factor in the pulmonary response to inhaled bacterial endotoxin.
Burrell, R; Keller, GE; Lantz, RC, 1991
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic study of CsA showed that this lack of efficacy of combined treatment may be interpreted as the decreased CsA bioavailability observed when the animals also received RP 48740."( Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist.
Freiche, JC; Lang, J; Sedivy, P; Touraine, JL, 1990
)
0.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID83103Antiviral activity towards inhibition of replication of HIV-1-DAS infected monocyte-derived macrophage2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
AID157040Inhibition of PAF-induced platelet aggregation was determined using platelet rich plasma (PRP) of New Zealand rabbits.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (42.86)18.7374
1990's11 (52.38)18.2507
2000's1 (4.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.29 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]